The DOI matches its Crossref record; 184 of the 184 references it cites were found in a registry or an index.
Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy
Open accessAbstract
Recent advances in cancer treatment have emerged from new immunotherapies targeting T-cell inhibitory receptors, including CTLA-4 and PD-1. In this context, anti-CTLA-4 and anti-PD-1 monoclonal antibodies (mAb) have demonstrated survival benefits in numerous cancers, including melanoma and non-small-cell lung carcinoma (NSCLC). PD-1-expressing CD8+ T lymphocytes appear to play a major role in the response to these immune checkpoint inhibitors (ICI). Cytotoxic T lymphocytes (CTL) eliminate malignant cells through recognition by the T-cell receptor (TCR) of specific antigenic peptides presented on the surface of cancer cells by major histocompatibility complex class I (MHC-I)/beta-2-microglobulin (beta2m) complexes, and through killing of target cells, mainly by releasing the content of secretory lysosomes containing perforin and granzyme B. T-cell adhesion molecules and, in particular, lymphocyte-function-associated antigen-1 (LFA-1) and CD103 integrins, and their cognate ligands, respectively, intercellular adhesion molecule 1 (ICAM-1) and E-cadherin, on target cells, are involved in strengthening the interaction between CTL and tumor cells. Tumor-specific CTL have been isolated from tumor-infiltrating lymphocytes (TIL) and peripheral blood lymphocytes (PBL) of patients with varied cancers. TCRbeta-chain gene usage indicated that CTL identified in vitro selectively expanded in vivo at the tumor site compared to autologous PBL. Moreover, functional studies indicated that these CTL mediate human leukocyte antigen class I (HLA-I)-restricted cytotoxic activity toward autologous tumor cells. Several of them recognize truly tumor-specific antigens (TSA) encoded by mutated genes, also known as neoantigens, which likely play a key role in anti-tumor CD8 T-cell immunity. Accordingly, it has been shown that the presence of T lymphocytes directed toward tumor neoantigens is associated with patient response to immunotherapies, including ICI, adoptive cell transfer (ACT) and the dendritic cell-(DC)-based vaccine. These tumor-specific mutation-derived antigens open up new perspectives for development of effective second-generation therapeutic cancer vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 2×
“Accumulating evidence indicates that preexisting antitumor CD8+ T cells predict the efficacy of ICI therapy (124, 173).”
BackgroundHerbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Next-generation DNA sequencing
Shendure, J., & Ji, H. (2008) · Nature Biotechnology · doi:10.1038/nbt1486 · Cited by 4,509
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 1×
“While the CTLA-4 blockade reduces the activation threshold required for T-cell priming (166), the PD1/PD-L1 blockade in certain T-cell subpopulations (167) at least partly reverses immune alterations such as exhaustion (168).”
BackgroundNagata, S., & Golstein, P. (1995) · Science · doi:10.1126/science.7533326 · Cited by 3,979
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · cited 1×
“Resistance to anti-PD-1 of tumors with a high mutational load was associated with defects in pathways involved in IFNγ-receptor signaling and antigen presentation by MHC-I molecules, concomitant with a truncating mutation in the gene encoding β2m (176, 177).”
BackgroundT-cell antigen receptor genes and T-cell recognition
Davis, M. M., & Bjorkman, P. J. (1988) · Nature · doi:10.1038/334395a0 · Cited by 3,202
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,972
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488 · cited 1×
“In this regard, personalized RNA-based mutanome vaccines, alone or in combination with anti-PD-1, induced effective T-cell responses against multiple vaccine neoepitopes and resulted in sustained progression-free survival (84).”
BackgroundKalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,140
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051424 · Cited by 2,135
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
Im, S. J., Hashimoto, M., Gerner, M. Y., Lee, J., Kissick, H. T., Burger, M. C., Shan, Q., Hale, J. S., Lee, J., Nasti, T. H., et al. (2016) · Nature · doi:10.1038/nature19330 · Cited by 2,070
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Cancer immunotherapy via dendritic cells
Palucka, K., & Banchereau, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3258 · Cited by 2,049
Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., et al. (1998) · Nature Medicine · doi:10.1038/nm0398-321 · Cited by 1,784
Activating Receptors and Coreceptors Involved in Human Natural Killer Cell-Mediated Cytolysis
Moretta, A., Bottino, C., Vitale, M., Pende, D., Cantoni, C., Mingari, M. C., Biassoni, R., & Moretta, L. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.197 · Cited by 1,778
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Robbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2537 · Cited by 1,632
Johnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,418
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337
Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy
Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300
Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S., Borquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,286
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. A., Ly, A., Lie, W.-R., Hildebrand, W. H., Mardis, E. R., et al. (2015) · Science · doi:10.1126/science.aaa3828 · Cited by 1,285
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., et al. (2015) · Nature · doi:10.1038/nature14426 · Cited by 1,243
Cosman, D., Müllberg, J., Sutherland, C. L., Chin, W., Armitage, R., Fanslow, W., Kubin, M., & Chalupny, N. J. (2001) · Immunity · doi:10.1016/s1074-7613(01)00095-4 · Cited by 1,232
Marincola, F. M., Jaffee, E. M., Hicklin, D. J., & Ferrone, S. (1999) · Advances in Immunology · doi:10.1016/s0065-2776(08)60911-6 · Cited by 1,174
Melief, C. J. M., van Hall, T., Arens, R., Ossendorp, F., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,164
A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.-H., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,154
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Coulie, P. G., Van den Eynde, B. J., van der Bruggen, P., & Boon, T. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3670 · Cited by 1,138
Robbins, P. F., Lu, Y.-C., El-Gamil, M., Li, Y. F., Gross, C., Gartner, J., Lin, J. C., Teer, J. K., Cliften, P., Tycksen, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3161 · Cited by 1,072
Broad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB
Groh, V., Rhinehart, R., Secrist, H., Bauer, S., Grabstein, K. H., & Spies, T. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6879 · Cited by 1,028
DEGRADATION OF CELL PROTEINS AND THE GENERATION OF MHC CLASS I-PRESENTED PEPTIDES
Rock, K. L., & Goldberg, A. L. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.739 · Cited by 921
The role of TNF superfamily members in T-cell function and diseases
Croft, M. (2009) · Nature Reviews Immunology · doi:10.1038/nri2526 · Cited by 920
Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
Hunder, N. N., Wallen, H., Cao, J., Hendricks, D. W., Reilly, J. Z., Rodmyre, R., Jungbluth, A., Gnjatic, S., Thompson, J. A., & Yee, C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800251 · Cited by 911
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
Melero, I., Shuford, W. W., Newby, S. A., Aruffo, A., Ledbetter, J. A., Hellström, K. E., Mittler, R. S., & Chen, L. (1997) · Nature Medicine · doi:10.1038/nm0697-682 · Cited by 898
Beatty, G. L., Haas, A. R., Maus, M. V., Torigian, D. A., Soulen, M. C., Plesa, G., Chew, A., Zhao, Y., Levine, B. L., Albelda, S. M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0170 · Cited by 864
Roh, W., Chen, P.-L., Reuben, A., Spencer, C. N., Prieto, P. A., Miller, J. P., Gopalakrishnan, V., Wang, F., Cooper, Z. A., Reddy, S. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah3560 · Cited by 859
Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients
Baitsch, L., Baumgaertner, P., Devêvre, E., Raghav, S. K., Legat, A., Barba, L., Wieckowski, S., Bouzourene, H., Deplancke, B., Romero, P., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46102 · Cited by 845
Gros, A., Parkhurst, M. R., Tran, E., Pasetto, A., Robbins, P. F., Ilyas, S., Prickett, T. D., Gartner, J. J., Crystal, J. S., Roberts, I. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4051 · Cited by 829
Robbins, P. F., Kassim, S. H., Tran, T. L. N., Crystal, J. S., Morgan, R. A., Feldman, S. A., Yang, J. C., Dudley, M. E., Wunderlich, J. R., Sherry, R. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2708 · Cited by 807
Cutting Edge: Control of CD8+ T Cell Activation by CD4+CD25+ Immunoregulatory Cells
Piccirillo, C. A., & Shevach, E. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.3.1137 · Cited by 716
Vaccines for established cancer: overcoming the challenges posed by immune evasion
van der Burg, S. H., Arens, R., Ossendorp, F., van Hall, T., & Melief, C. J. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.16 · Cited by 709
Dudley, M. E., Wunderlich, J. R., Shelton, T. E., Even, J., & Rosenberg, S. A. (2003) · Journal of Immunotherapy · doi:10.1097/00002371-200307000-00005 · Cited by 701
Linnemann, C., van Buuren, M. M., Bies, L., Verdegaal, E. M. E., Schotte, R., Calis, J. J. A., Behjati, S., Velds, A., Hilkmann, H., Atmioui, D. E., et al. (2015) · Nature Medicine · doi:10.1038/nm.3773 · Cited by 679
The role of CD4+ T cell responses in antitumor immunity
Pardoll, D. M., & Topalian, S. L. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80228-8 · Cited by 672 · cited 10×
“Involvement of CD4+ T cells in regulating antitumor immunity was associated with their help in priming of CD8+ T cells, through activation of APC and an increase in antigen presentation by major histocompatibility complex class I (MHC-I) molecules via secretion of cytokines such as IFNγ (29, 30).”
BackgroundInfluentialThe Critical Need for CD4 Help in Maintaining Effective Cytotoxic T Lymphocyte Responses
Kalams, S. A., & Walker, B. D. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2199 · Cited by 660
HUMAN T CELL RESPONSES AGAINST MELANOMA
Boon, T., Coulie, P. G., Eynde, B. J. V. D., & Bruggen, P. V. D. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090733 · Cited by 651
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy
Łuksza, M., Riaz, N., Makarov, V., Balachandran, V. P., Hellmann, M. D., Solovyov, A., Rizvi, N. A., Merghoub, T., Levine, A. J., Chan, T. A., et al. (2017) · Nature · doi:10.1038/nature24473 · Cited by 646
Pannetier, C., Cochet, M., Darche, S., Casrouge, A., Zöller, M., & Kourilsky, P. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.9.4319 · Cited by 634
Djenidi, F., Adam, J., Goubar, A., Durgeau, A., Meurice, G., de Montpréville, V., Validire, P., Besse, B., & Mami-Chouaib, F. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402711 · Cited by 622
Self-citationRobbins, P. F., El-Gamil, M., Li, Y. F., Kawakami, Y., Loftus, D., Appella, E., & Rosenberg, S. A. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.1185 · Cited by 550 · cited 1×
“Beta-catenin Melanoma A24 SYLDSGIHF 29–37 (58)”
Characterization of CD4+ CTLs Ex Vivo
Appay, V., Zaunders, J. J., Papagno, L., Sutton, J., Jaramillo, A., Waters, A., Easterbrook, P., Grey, P., Smith, D., McMichael, A. J., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.11.5954 · Cited by 545
Tumor antigens recognized by T cells
Boon, T., Coulie, P. G., & Van den Eynde, B. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)80020-5 · Cited by 537
Targeting tumours with genetically enhanced T lymphocytes
Sadelain, M., Rivière, I., & Brentjens, R. (2003) · Nature Reviews Cancer · doi:10.1038/nrc971 · Cited by 535
Exploiting the curative potential of adoptive T‐cell therapy for cancer
Hinrichs, C. S., & Rosenberg, S. A. (2014) · Immunological Reviews · doi:10.1111/imr.12132 · Cited by 466
A listing of human tumor antigens recognized by T cells: March 2004 update
Novellino, L., Castelli, C., & Parmiani, G. (2005) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-004-0560-6 · Cited by 466
Neoantigen landscape dynamics during human melanoma–T cell interactions
Verdegaal, E. M. E., de Miranda, N. F. C. C., Visser, M., Harryvan, T., van Buuren, M. M., Andersen, R. S., Hadrup, S. R., van der Minne, C. E., Schotte, R., Spits, H., et al. (2016) · Nature · doi:10.1038/nature18945 · Cited by 461
The response of autologous T cells to a human melanoma is dominated by mutated neoantigens
Lennerz, V., Fatho, M., Gentilini, C., Frye, R. A., Lifke, A., Ferel, D., Wölfel, C., Huber, C., & Wölfel, T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500090102 · Cited by 456
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors
Kochenderfer, J. N., & Rosenberg, S. A. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.46 · Cited by 451
'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations
Tran, E., Robbins, P. F., & Rosenberg, S. A. (2017) · Nature Immunology · doi:10.1038/ni.3682 · Cited by 443
Coulie, P. G., Lehmann, F., Lethé, B., Herman, J., Lurquin, C., Andrawiss, M., & Boon, T. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7976 · Cited by 423
Ahrends, T., Spanjaard, A., Pilzecker, B., Bąbała, N., Bovens, A., Xiao, Y., Jacobs, H., & Borst, J. (2017) · Immunity · doi:10.1016/j.immuni.2017.10.009 · Cited by 413
Cancer Immunotherapy With Peptide-Based Vaccines: What Have We Achieved? Where Are We Going?
Parmiani, G., Castelli, C., Dalerba, P., Mortarini, R., Rivoltini, L., Marincola, F. M., & Anichini, A. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.11.805 · Cited by 401
Lu, Y.-C., Yao, X., Crystal, J. S., Li, Y. F., El-Gamil, M., Gross, C., Davis, L., Dudley, M. E., Yang, J. C., Samuels, Y., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0433 · Cited by 401
Profiling the T-cell receptor beta-chain repertoire by massively parallel sequencing
Freeman, J. D., Warren, R. L., Webb, J. R., Nelson, B. H., & Holt, R. A. (2009) · Genome Research · doi:10.1101/gr.092924.109 · Cited by 385
Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients
Cha, E., Klinger, M., Hou, Y., Cummings, C., Ribas, A., Faham, M., & Fong, L. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008211 · Cited by 383
Stevanović, S., Pasetto, A., Helman, S. R., Gartner, J. J., Prickett, T. D., Howie, B., Robins, H. S., Robbins, P. F., Klebanoff, C. A., Rosenberg, S. A., et al. (2017) · Science · doi:10.1126/science.aak9510 · Cited by 383
Gorski, J., Yassai, M., Zhu, X., Kissela, B., Keever, C., & Flomenberg, N. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.3.1521.a · Cited by 381
The Makings of a Tumor Rejection Antigen
Gilboa, E. (1999) · Immunity · doi:10.1016/s1074-7613(00)80101-6 · Cited by 381
Anti–CTLA-4 therapy broadens the melanoma-reactive CD8 + T cell response
Kvistborg, P., Philips, D., Kelderman, S., Hageman, L., Ottensmeier, C., Joseph-Pietras, D., Welters, M. J. P., van der Burg, S., Kapiteijn, E., Michielin, O., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008918 · Cited by 378
Promiscuity and the single receptor: NKG2D
Eagle, R. A., & Trowsdale, J. (2007) · Nature Reviews Immunology · doi:10.1038/nri2144 · Cited by 374
Mechanisms regulating T-cell infiltration and activity in solid tumors
Lanitis, E., Dangaj, D., Irving, M., & Coukos, G. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx238 · Cited by 369
Gorski, J., Yassai, M., Zhu, X., Kissela, B., Kissella B [corrected to Kissela, B., Keever, C., & Flomenberg, N. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.10.5109 · Cited by 342
Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40
Sugamura, K., Ishii, N., & Weinberg, A. D. (2004) · Nature Reviews Immunology · doi:10.1038/nri1371 · Cited by 335
Alt, F. W., Oltz, E. M., Young, F., Gorman, J., Taccioli, G., & Chen, J. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90043-7 · Cited by 324
A CASP-8 Mutation Recognized by Cytolytic T Lymphocytes on a Human Head and Neck Carcinoma
Mandruzzato, S., Brasseur, F., Andry, G., Boon, T., & Bruggen, P. V. D. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.5.785 · Cited by 321
Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know
Rosenberg, S. A. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.116 · Cited by 312
Landscape of tumor-infiltrating T cell repertoire of human cancers
Li, B., Li, T., Pignon, J.-C., Wang, B., Wang, J., Shukla, S. A., Dou, R., Chen, Q., Hodi, F. S., Choueiri, T. K., et al. (2016) · Nature Genetics · doi:10.1038/ng.3581 · Cited by 306
Cloning Genes Encoding MHC Class II-Restricted Antigens: Mutated CDC27 as a Tumor Antigen
Wang, R.-F., Wang, X., Atwood, A. C., Topalian, S. L., & Rosenberg, S. A. (1999) · Science · doi:10.1126/science.284.5418.1351 · Cited by 300
Chandran, S. S., Somerville, R. P. T., Yang, J. C., Sherry, R. M., Klebanoff, C. A., Goff, S. L., Wunderlich, J. R., Danforth, D. N., Zlott, D., Paria, B. C., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30251-6 · Cited by 292
Butterfield, L. H. (2015) · BMJ · doi:10.1136/bmj.h988 · Cited by 272
Therapeutic cancer vaccines: Are we there yet?
Klebanoff, C. A., Acquavella, N., Yu, Z., & Restifo, N. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00979.x · Cited by 271 · cited 1×
“First-generation cancer vaccines based on non-mutant TAA, also termed shared antigens because they are expressed by many patients’ tumors, such as MART-1, gp100, tyrosinase, TRP-2, NY-ESO-1, MAGE-A3, and Her2/neu or telomerase proteins, were shown to be immunogenic and capable of inducing clinical responses in only a…”
BackgroundFloc'h, A. L., Jalil, A., Vergnon, I., Chansac, B. L. M., Lazar, V., Bismuth, G., Chouaib, S., & Mami-Chouaib, F. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061524 · Cited by 269
Self-citationImmune Suppression in the Tumor Microenvironment
Gajewski, T. F., Meng, Y., & Harlin, H. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000199193.29048.56 · Cited by 265
Adoptive Immunotherapy for Cancer or Viruses
Maus, M. V., Fraietta, J. A., Levine, B. L., Kalos, M., Zhao, Y., & June, C. H. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120136 · Cited by 264
Ligands for natural killer cell receptors: redundancy or specificity
Cerwenka, A., & Lanier, L. L. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1810113.x · Cited by 248
Dudley, M. E., Gross, C. A., Somerville, R. P. T., Hong, Y., Schaub, N. P., Rosati, S. F., White, D. E., Nathan, D., Restifo, N. P., Steinberg, S. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.6441 · Cited by 235
Heemskerk, B., Kvistborg, P., & Schumacher, T. N. M. (2013) · The EMBO Journal · doi:10.1038/emboj.2012.333 · Cited by 227
The nature of molecular recognition by T cells
Davis, S. J., Ikemizu, S., Evans, E. J., Fugger, L., Bakker, T. R., & van der Merwe, P. A. (2003) · Nature Immunology · doi:10.1038/ni0303-217 · Cited by 226
(2017) · doi:10.1158/2159-8290.cd-17-0256 · Cited by 223
The new paradigm of flow cell sequencing: Table 1.
Holt, R. A., & Jones, S. J. M. (2008) · Genome Research · doi:10.1101/gr.073262.107 · Cited by 217
Sequence analysis of T-cell repertoires in health and disease
Woodsworth, D. J., Castellarin, M., & Holt, R. A. (2013) · Genome Medicine · doi:10.1186/gm502 · Cited by 192
Biochemical Identification of a Mutated Human Melanoma Antigen Recognized by CD4+ T Cells
Pieper, R., Christian, R. E., Gonzales, M. I., Nishimura, M. I., Gupta, G. P., Settlage, R. E., Shabanowitz, J., Rosenberg, S. A., Hunt, D. F., & Topalian, S. L. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.5.757 · Cited by 190
Pasetto, A., Gros, A., Robbins, P. F., Deniger, D. C., Prickett, T. D., Matus-Nicodemos, R., Douek, D. C., Howie, B., Robins, H., Parkhurst, M. R., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0001 · Cited by 190
Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation
Wing, K., Yamaguchi, T., & Sakaguchi, S. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.06.002 · Cited by 183
Parkhurst, M., Gros, A., Pasetto, A., Prickett, T., Crystal, J. S., Robbins, P., & Rosenberg, S. A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2680 · Cited by 182
Anikeeva, N., Somersalo, K., Sims, T. N., Thomas, V. K., Dustin, M. L., & Sykulev, Y. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502467102 · Cited by 179
High-throughput identification of antigen-specific TCRs by TCR gene capture
Linnemann, C., Heemskerk, B., Kvistborg, P., Kluin, R. J. C., Bolotin, D. A., Chen, X., Bresser, K., Nieuwland, M., Schotte, R., Michels, S., et al. (2013) · Nature Medicine · doi:10.1038/nm.3359 · Cited by 177
Antigen Spreading Contributes to MAGE Vaccination-Induced Regression of Melanoma Metastases
Corbière, V., Chapiro, J., Stroobant, V., Ma, W., Lurquin, C., Lethé, B., van Baren, N., Van den Eynde, B. J., Boon, T., & Coulie, P. G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2693 · Cited by 175
Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination
Melero, I., Grimaldi, A. M., Perez-Gracia, J. L., & Ascierto, P. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2214 · Cited by 170
Chmielewski, M., Hombach, A. A., & Abken, H. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00371 · Cited by 167
Wick, D. A., Webb, J. R., Nielsen, J. S., Martin, S. D., Kroeger, D. R., Milne, K., Castellarin, M. L., Twumasi‐Boateng, K., Watson, P. H., Holt, R. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2147 · Cited by 167
Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants
van Hall, T., Wolpert, E. Z., van Veelen, P., Laban, S., van der Veer, M., Roseboom, M., Bres, S., Grufman, P., de Ru, A., Meiring, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1381 · Cited by 160
Wang, H. Y., Peng, G., Guo, Z., Shevach, E. M., & Wang, R. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.5.2661 · Cited by 157
Brändle, D., Brasseur, F., Weynants, P., Boon, T., & den Eynde, B. J. V. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.6.2501 · Cited by 144
Butterfield, L. H., & 易宗毕 (2015) · doi:10.3760/cma.j.issn.1007-9742.2015.11.117 · Cited by 144
Wang, R., Wang, X., & Rosenberg, S. A. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.10.1659 · Cited by 143
Speiser, D. E., Baumgaertner, P., Voelter, V., Devêvre, E., Barbey, C., Rufer, N., & Romero, P. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800080105 · Cited by 137
Echchakir, H., Mami‐Chouaib, F., Vergnon, I., Baurain, J., Karanikas, V., Chouaïb, S., & Coulie, P. G. (2001) · PubMed · Cited by 132
Self-citationDonia, M., Andersen, R. S., Kjeldsen, J. W., Fagone, P., Ahmad, S. M., Nicoletti, F., Andersen, M. H., Straten, P. T., & Svane, I. M. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2956 · Cited by 131
Irving, M. B., Zoete, V., Hebeisen, M., Schmid, D. A., Baumgärtner, P., Guillaume, P., Romero, P. J., Speiser, D. E., Luescher, I. F., Rufer, N., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.357673 · Cited by 128
Huang, J., El‐Gamil, M., Dudley, M. E., Li, Y. F., Rosenberg, S. A., & Robbins, P. F. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.10.6057 · Cited by 127
Human Tumor Antigens Yesterday, Today, and Tomorrow
Finn, O. J. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0112 · Cited by 126
The secretory synapse: the secrets of a serial killer
Bossi, G., Trambas, C., Booth, S., Clark, R., Stinchcombe, J. C., & Griffiths, G. M. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18913.x · Cited by 122
The Final Touches Make Perfect the Peptide-MHC Class I Repertoire
Hammer, G. E., Kanaseki, T., & Shastri, N. (2007) · Immunity · doi:10.1016/j.immuni.2007.04.003 · Cited by 119
Karanikas, V., Colau, D., Baurain, J., Chiari, R., Thonnard, J., Gutierrez-Roelens, I., Goffinet, C., SCHAFTINGEN, E. V., Weynants, P., Boon, T., et al. (2001) · PubMed · Cited by 119
Even, J., Lim, A., Puisieux, I., Ferradini, L., Dietrich, P.-Y., Toubert, A., Hercend, T., Triebel, F., Pannetier, C., & Kourilsky, P. (1995) · Research in Immunology · doi:10.1016/0923-2494(96)80240-9 · Cited by 111
Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes
Kessler, J. H., Khan, S., Seifert, U., Gall, S. L., Chow, K. M., Paschen, A., Bres-Vloemans, S. A., de Ru, A., van Montfoort, N., Franken, K. L. M. C., et al. (2010) · Nature Immunology · doi:10.1038/ni.1974 · Cited by 109
Profiling tissue-resident T cell repertoires by RNA sequencing
Brown, S. D., Raeburn, L. A., & Holt, R. A. (2015) · Genome Medicine · doi:10.1186/s13073-015-0248-x · Cited by 106
Baurain, J., Colau, D., van Baren, N., Landry, C., Martelange, V., Vikkula, M., Boon, T., & Coulie, P. G. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.11.6057 · Cited by 101
Zorn, E., & Hercend, T. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199902)29:02<592::aid-immu592>3.0.co;2-2 · Cited by 100
Immunotherapy: The Path to Win the War on Cancer?
Topalian, S. L., Wolchok, J. D., Chan, T. A.-T., Mellman, I., Palucka, K., Banchereau, J., Rosenberg, S. A., & Wittrup, K. D. (2015) · Cell · doi:10.1016/j.cell.2015.03.045 · Cited by 99
Hogan, K. T., Eisinger, D. P., Cupp, S. B., Lekstrom, K. J., Deacon, D. H., Shabanowitz, J., Hunt, D. F., Engelhard, V. H., Slingluff, C. L., & Ross, M. M. (1998) · PubMed · Cited by 91
Selected signalling proteins recruited to the T‐cell receptor–CD3 complex
Ngoenkam, J., Schamel, W. W. A., & Pongcharoen, S. (2017) · Immunology · doi:10.1111/imm.12809 · Cited by 89
A ras- Mutated Peptide Targeted by CTL Infiltrating a Human Melanoma Lesion
Linard, B., Bezieau, S., Benlalam, H., Labarrière, N., Guilloux, Y., Diez, E., & Jotereau, F. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.9.4802 · Cited by 88
Lim, A., Baron, V. T., Ferradini, L., Bonneville, M., Kourilsky, P., & Pannetier, C. (2002) · Journal of Immunological Methods · doi:10.1016/s0022-1759(02)00004-2 · Cited by 86
Dorothée, G., Vergnon, I., Menez, J., Echchakir, H., Grunenwald, D. H., Kubin, M. Z., Chouaïb, S., & Mami‐Chouaib, F. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.2.809 · Cited by 86
Self-citationSlingluff, C. L., Cox, A. L., Stover, J. M., Moore, M. M., Hunt, D. F., & Engelhard, V. H. (1994) · PubMed · Cited by 84
TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors
Doorduijn, E. M., Sluijter, M., Querido, B. J., Oliveira, C. C., Achour, A., OSSENDORP, F. A., van der Burg, S. H., & van Hall, T. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83671 · Cited by 82
Hua, F., Yamaguchi, R., Liu, X., Daigo, Y., Yew, P. Y., Tanikawa, C., Matsuda, K., Imoto, S., Miyano, S., & Nakamura, Y. (2014) · OncoImmunology · doi:10.4161/21624011.2014.968467 · Cited by 80
Chiari, R., Foury, F., Plaen, E. D., Baurain, J., Thonnard, J., & Coulie, P. G. (1999) · PubMed · Cited by 79
Hage, F. E., Stroobant, V., Vergnon, I., Baurain, J., Echchakir, H., Lazar, V., Chouaı̈b, S., Coulie, P. G., & Mami‐Chouaib, F. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802753105 · Cited by 78
Self-citationAn Antigen Recognized by Autologous CTLs on a Human Bladder Carcinoma
Guéguen, M., Patard, J., Gaugler, B., Brasseur, F., Renauld, J., Cangh, P. J. V., Boon, T., & den Eynde, B. J. V. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.12.6188 · Cited by 72
Yasukawa, M., Ohminami, H., Yakushijin, Y., Arai, J. A., Hasegawa, A., Ishida, Y., & Fujita, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.10.6100 · Cited by 67
Chimeric Antigen Receptor ( CAR ) therapy for multiple myeloma
Atanackovic, D., Radhakrishnan, S. V., Bhardwaj, N., & Luetkens, T. (2016) · British Journal of Haematology · doi:10.1111/bjh.13889 · Cited by 65
Role of CD4 + Cytotoxic T Lymphocytes in the Control of Viral Diseases and Cancer
Martorelli, D., Muraro, E., Merlo, A., Turrini, R., Rosato, A., & Dolcetti, R. (2010) · International Reviews of Immunology · doi:10.3109/08830185.2010.489658 · Cited by 64
Echchakir, H., Vergnon, I., Dorothée, G., Grunenwald, D. H., Chouaïb, S., & Mami‐Chouaib, F. (2000) · International Immunology · doi:10.1093/intimm/12.4.537 · Cited by 64
Self-citationProduction of an antigenic peptide by insulin-degrading enzyme
Parmentier, N., Stroobant, V., Colau, D., de Diesbach, P., Morel, S., Chapiro, J., Endert, P. V., & den Eynde, B. J. V. (2010) · Nature Immunology · doi:10.1038/ni.1862 · Cited by 63
Takenoyama, M., Baurain, J., Yasuda, M., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21594 · Cited by 61
Curing Mice with Large Tumors by Locally Delivering Combinations of Immunomodulatory Antibodies
Dai, M., Yip, Y. Y., Hellström, I., & Hellström, K. E. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1339 · Cited by 60
Echchakir, H., Dorothée, G., Vergnon, I., Menez, J., Chouaïb, S., & Mami‐Chouaib, F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.142308199 · Cited by 59
Self-citationExome Sequencing to Predict Neoantigens in Melanoma
Pritchard, A. L., Burel, J. G., Neller, M. A., Hayward, N. K., López, J. A., Fatho, M., Lennerz, V., Wölfel, T., & Schmidt, C. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0088 · Cited by 59
Adoptive cell therapy: Honing that killer instinct
Humphries, C. A. (2013) · Nature · doi:10.1038/504s13a · Cited by 58
Miller, M. J., Foy, K. C., & Kaumaya, P. T. P. (2013) · PubMed · Cited by 54
Novellino, L., Renkvist, N., Rini, F., Mazzocchi, A., Rivoltini, L., Greco, A., Deho, P., Squarcina, P., Robbins, P. F., Parmiani, G., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.12.6363 · Cited by 54
In vivo local expansion of clonal T cell subpopulations in renal cell carcinoma.
Gaudin, C., Dietrich, P.-Y., Robache, S., Guillard, M., Escudier, B. J., Terrier-Lacombe, M.-J., Kumar, A., Triebel, F., & Caignard, A. (1995) · PubMed · Cited by 53
Ray, S., Chhabra, A., Chakraborty, N. G., Hegde, U. P., Dorsky, D. I., Chodon, T., von Euw, E., Comin-Anduix, B., Koya, R. C., Ribas, A., et al. (2010) · Clinical Immunology · doi:10.1016/j.clim.2010.04.013 · Cited by 51
Adoptive immunotherapy for cancer: the next generation of gene‐engineered immune cells
Berry, L. J., Moeller, M., & Darcy, P. K. (2009) · Tissue Antigens · doi:10.1111/j.1399-0039.2009.01336.x · Cited by 47
New Role of Signal Peptide Peptidase To Liberate C-Terminal Peptides for MHC Class I Presentation
Oliveira, C. C., Querido, B. J., Sluijter, M., de Groot, A. F., van der Zee, R., Rabelink, M. J. W. E., Hoeben, R. C., OSSENDORP, F. A., van der Burg, S. H., & van Hall, T. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301496 · Cited by 45
Durgeau, A., Hage, F. E., Vergnon, I., Validire, P., de Montpréville, V., Besse, B., Soria, J., van Hall, T., & Mami‐Chouaib, F. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1102060 · Cited by 44
Self-citationQuakkelaar, E. D., & Melief, C. J. M. (2012) · Advances in immunology · doi:10.1016/b978-0-12-396548-6.00004-4 · Cited by 41
Identification of a Mutated Fibronectin As a Tumor Antigen Recognized by CD4+T Cells
Wang, H. Y., Zhou, J., Zhu, K., Riker, A. I., Marincola, F. M., & Wang, R. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020141 · Cited by 41
Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytes.
Maccalli, C., Li, Y. F., El‐Gamil, M., Rosenberg, S. A., & Robbins, P. F. (2003) · PubMed · Cited by 39
Profiling model T-cell metagenomes with short reads
Warren, R. M., Nelson, B. H., & Holt, R. A. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp010 · Cited by 39
Maccalli, C., Nonaka, D., Piris, A., Pende, D., Rivoltini, L., Castelli, C., & Parmiani, G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1166 · Cited by 38
Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation
Adler, A. J., & Vella, A. T. (2012) · OncoImmunology · doi:10.4161/onci.22837 · Cited by 28
Primer sets for cloning the human repertoire of T cell Receptor Variable regions
Boria, I., Cotella, D., Dianzani, I., Santoro, C., & Sblattero, D. (2008) · BMC Immunology · doi:10.1186/1471-2172-9-50 · Cited by 24
Differentially induced expression of C-type lectins in activated lymphocytes
Eichler, W., Ruschpler, P., Wobus, M., & Dr�ssler, K. (2001) · Journal of Cellular Biochemistry · doi:10.1002/jcb.1107 · Cited by 24
Vigneron, N., Ooms, A., Morel, S., Degiovanni, G., & den Eynde, B. J. V. (2002) · PubMed · Cited by 20
Zennadi, R., Abdel-Wahab, Z., Seigler, H. F., & Darrow, T. L. (2001) · Cellular Immunology · doi:10.1006/cimm.2001.1809 · Cited by 14
Lerret, N. M., & Marzo, A. L. (2013) · OncoImmunology · doi:10.4161/onci.22731 · Cited by 11
Wang, E., Selleri, S., & Marincola, F. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2150 · Cited by 9
Cited by
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127
Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment
Harjunpää, H., Llort Asens, M., Guenther, C., & Fagerholm, S. C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01078 · Cited by 764
Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment
Fu, C., & Jiang, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03059 · Cited by 598
Teaching an old dog new tricks: next-generation CAR T cells
Tokarew, N., Ogonek, J., Endres, S., von Bergwelt-Baildon, M., & Kobold, S. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0325-1 · Cited by 440
Metadata
- Authors
- Durgeau, A., Virk, Y., Corgnac, S., & Mami-Chouaib, F.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2018-01-22
- Volume
- 9
- Pages
- 14-14
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2785934310
- Cited by
- 495
- References
- 184
- FWCI
- 19.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.